Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Malaria01:29

Malaria

Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Symbiosis00:58

Symbiosis

Symbiotic relationships are long-term, close interactions between individuals of different species that affect the distribution and abundance of those species. When a relationship is beneficial to both species, this is called mutualism. When the relationship is beneficial to one species but neither beneficial nor harmful to the other species, this is called commensalism. When one organism is harmed to benefit another, the relationship is known as parasitism. These types of relationships often...
Rocky Mountain Spotted Fever01:26

Rocky Mountain Spotted Fever

Rocky Mountain Spotted Fever (RMSF) is a severe tick-borne illness caused by Rickettsia rickettsii, a Gram-negative, coccobacillary bacterium. This pathogen is an obligate intracellular parasite, requiring a host cell for replication. Transmission occurs through the bite of an infected tick. In the United States, the most important vectors are Dermacentor variabilis (American dog tick) and Dermacentor andersoni (Rocky Mountain wood tick), though other tick species may also serve as vectors.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structure and functional diversity of antibodies targeting the <i>P. falciparum</i> circumsporozoite protein C-terminal domain.

bioRxiv : the preprint server for biology·2026
Same author

Transfer of breast milk IgA to infants after oral bivalent norovirus vaccination of post-partum women.

NPJ vaccines·2026
Same author

Sustained efficacy of the RTS,S/AS01<sub>E</sub> malaria vaccine over 50 months of follow-up when used in full-dose or fractional-dose regimens in young children in Ghana and Kenya: final results from an open-label, phase 2b, randomised controlled trial.

The Lancet. Global health·2025
Same author

Vaccine-Induced Antibodies to a C-Terminal Plasmodium falciparum Circumsporozoite Protein Epitope Associated With Protection Against Malaria Challenge.

The Journal of infectious diseases·2025
Same author

Plasmodium falciparum Parasitemia Does Not Diminish Neutralizing Antibody Responses After mRNA COVID-19 Booster Vaccination in HIV-infected Adults.

The Journal of infectious diseases·2025
Same author

Efficacy of RTS,S/AS01E Only Seen in Baseline Parasitemic and Not Baseline Aparasitemic Plasmodium falciparum-Exposed, Drug-Treated Kenyan Adults.

The Journal of infectious diseases·2025

Related Experiment Video

Updated: Jun 1, 2026

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds
07:14

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds

Published on: July 11, 2025

The RTS,S vaccine candidate for malaria.

Jason A Regules1, James F Cummings, Christian F Ockenhouse

  • 1Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA. jason.regules@us.army.mil

Expert Review of Vaccines
|May 25, 2011
PubMed
Summary

Developing an effective malaria vaccine is crucial for global health. The RTS,S/AS01 vaccine candidate, enhanced by potent adjuvants, shows safety, immunogenicity, and partial efficacy in diverse populations, with ongoing research for improvement.

More Related Videos

Myeloid Cell Isolation from Mouse Skin and Draining Lymph Node Following Intradermal Immunization with Live Attenuated Plasmodium Sporozoites
08:46

Myeloid Cell Isolation from Mouse Skin and Draining Lymph Node Following Intradermal Immunization with Live Attenuated Plasmodium Sporozoites

Published on: May 18, 2016

Generating Genetically Modified Plasmodium berghei Sporozoites
10:16

Generating Genetically Modified Plasmodium berghei Sporozoites

Published on: May 5, 2023

Related Experiment Videos

Last Updated: Jun 1, 2026

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds
07:14

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds

Published on: July 11, 2025

Myeloid Cell Isolation from Mouse Skin and Draining Lymph Node Following Intradermal Immunization with Live Attenuated Plasmodium Sporozoites
08:46

Myeloid Cell Isolation from Mouse Skin and Draining Lymph Node Following Intradermal Immunization with Live Attenuated Plasmodium Sporozoites

Published on: May 18, 2016

Generating Genetically Modified Plasmodium berghei Sporozoites
10:16

Generating Genetically Modified Plasmodium berghei Sporozoites

Published on: May 5, 2023

Area of Science:

  • Vaccinology
  • Infectious Disease Research
  • Global Health

Background:

  • Malaria remains a significant global health challenge, causing widespread illness and death.
  • Developing an effective malaria vaccine is a critical research priority.
  • The RTS,S/AS01 vaccine is the most advanced malaria vaccine candidate to date.

Purpose of the Study:

  • To review the development and validation of the RTS,S/AS01 malaria vaccine.
  • To highlight the role of adjuvants in enhancing vaccine potency.
  • To summarize the safety, immunogenicity, and efficacy findings of RTS,S-based formulations.

Main Methods:

  • Clinical trials and immunological assessments of RTS,S/AS01.
  • Evaluation of adjuvant impact on vaccine response.
  • Analysis of safety and tolerability data in target populations.

Main Results:

  • RTS,S/AS01 has demonstrated a favorable safety and tolerability profile.
  • The vaccine is immunogenic, eliciting a measurable immune response.
  • Partial efficacy has been observed in both malaria-naive and malaria-experienced individuals.

Conclusions:

  • RTS,S/AS01 is a well-developed and clinically validated malaria vaccine candidate.
  • Adjuvant optimization has been instrumental in improving vaccine potency.
  • Further research is underway to enhance the efficacy of RTS,S-based malaria vaccines.